Alnylam Pharmace Dl 0001【0HD2】銘柄情報

Alnylam Pharmace Dl 0001 (0HD2) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

100.80

( - )

買値

100.80

売値

100.80

出来高

0.00 日の範囲 0.00

100.80 52 週間の範囲 100.80

時価総額

13.458B

前日終値

100.80

始値

時刻

295

(O)

最終取引時間

21:29:51

財務取引量

VWAP

平均取引量 (3 か月)

US$ 1,099,121

発行済株式数

133,512,573

配当利回り

PER

76.72

1 株当たり利益 (EPS)

3.95

歳入

4.29B

純利益

537.99M

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATT... Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts. 詳細を表示

セクター

業界

ウェブサイト

www.alnylam.com

本社

Cambridge, United States

設立

2026

Alnylam Pharmace Dl 0001 is listed in the sector of the ロンドン証券取引所 with ticker 0HD2. The last closing price for Alnylam Pharmace Dl 0001 was US$100.80. Over the last year, Alnylam Pharmace Dl 0001 shares have traded in a share price range of US$ 100.80 to US$ 100.80.

Alnylam Pharmace Dl 0001 currently has 133,512,573 shares in issue. The market capitalisation of Alnylam Pharmace Dl 0001 is US$13.46 billion. Alnylam Pharmace Dl 0001 has a price to earnings ratio (PE ratio) of 76.72.

表示するニュースはありません。

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	100.8	100.8	100.8	44	100.8	DE
26	100.8	100.8	100.8	178	100.8	DE
52	100.8	100.8	100.8	369	100.8	DE
156	100.8	100.8	100.8	708	100.8	DE
260	100.8	100.8	100.8	564	100.8	DE